|
|
News Breaks | | | | November 15, 2012 | | 07:22 EDT |  | RXII | RXi Pharmaceuticals announces results of Phase 1 RXI-109 study
RXi Pharmaceuticals announced the pharmacokinetic results of their single dose Phase 1 study with RXI-109 in healthy subjects. This drug candidate is a highly selective CTGF targeting sd-rxRNA compound that is administered through intradermal injections to prevent or reduce dermal scarring following surgery or trauma, as well as for the management of hypertrophic scars and keloids. In this study, 15 volunteers divided over 5 cohorts received single intradermal injections in a dose escalating manner, and blood was drawn at various time points to evaluate the distribution of the drug beyond the injected tissue, into the systemic circulation. Previous primate toxicology work with RXI-109 had shown that the peak blood levels obtained after intradermal injections with 10 mg/kg were approximately 3.5% of the peak levels obtained after intravenous injections with the same dose. With the different doses in the primate study, the dermal and systemic side effects in the animals were minimal. The calculated relative systemic exposure in the 15 volunteers was between 1 and 7% which is very similar to the systemic exposure in primates. As reported earlier, the drug was very well tolerated in all volunteers tested. | |
|
News For RXII From The Last 14 Days Check below for free stories on RXII the last two weeks. |
|
|
| There are no results for RXII |
|
|
|
|
|
|
